Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4.acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
1998

Enhancing Anti-Tumor Effects with DMXAA and 5-HT

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): CJ Lash, AE Li, M Rutland, BC Baguley, LJ Zwi, WR Wilson

Primary Institution: The University of Auckland

Hypothesis

Can the combination of DMXAA and 5-hydroxytryptamine (5-HT) improve anti-tumor effects in mice?

Conclusion

The combination of DMXAA and 5-HT significantly enhances anti-tumor activity in mice without increasing toxicity.

Supporting Evidence

  • DMXAA alone caused dose-dependent inhibition of blood flow.
  • Co-administration of 5-HT enhanced necrosis from 8.8% to 38%.
  • Combining DMXAA with 5-HT resulted in >99% necrosis at higher doses.

Takeaway

This study shows that mixing two medicines can make them work better against tumors in mice.

Methodology

Mice were treated with DMXAA and/or 5-HT, and tumor blood flow, necrosis, and growth delay were measured.

Limitations

The study was conducted in mice, which may not fully represent human responses.

Participant Demographics

C3H/HeN female mice, 22-25 g at the time of treatment.

Statistical Information

P-Value

0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication